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ABSTRACT
The molecular basis underlying the aberrant DNA-
methylation patterns in human cancer is largely
unknown. Altered DNA methyltransferase (DNMT)
activity is believed to contribute, as DNMT expres-
sion levels increase during tumorigenesis. Here, we
present evidence that the expression of DNMT3b
is post-transcriptionally regulated by HuR, an RNA-
binding protein that stabilizes and/or modulates
the translation of target mRNAs. The presence of
a putative HuR-recognition motif in the DNMT3b
3’UTR prompted studies to investigate if this tran-
script associated with HuR. The interaction between
HuR and DNMT3b mRNA was studied by immuno-
precipitation of endogenous HuR ribonucleoprotein
complexes followed by RT–qPCR detection of
DNMT3b mRNA, and by in vitro pulldown of biotiny-
lated DNMT3b RNAs followed by western blotting
detection of HuR. These studies revealed that bind-
ing of HuR stabilized the DNMT3b mRNA and
increased DNMT3b expression. Unexpectedly, cis-
platin treatment triggered the dissociation of the
[HuR-DNMT3b mRNA] complex, in turn promoting
DNMT3b mRNA decay, decreasing DNMT3b abun-
dance, and lowering the methylation of repeated
sequences and global DNA methylation. In sum-
mary, our data identify DNMT3b mRNA as a novel
HuR target, present evidence that HuR affects
DNMT3b expression levels post-transcriptionally,
and reveal the functional consequences of the
HuR-regulated DNMT3b upon DNA methylation
patterns.
INTRODUCTION
Methylation of DNA at 5-position of cytosine is the
predominant epigenetic modiﬁcation in mammals and
regulates critical biological phenomena such as
X-chromosome inactivation, genomic imprinting, chro-
matin structure and regulation of gene expression (1,2)
and has been shown to be essential for mammalian devel-
opment (1). Aberrations in DNA methylation play a
causal role in a variety of diseases, including cancer (3).
Cancer cells exhibit global DNA hypomethylation and
speciﬁc promoter hypermethylation of tumor-suppressor
genes (4). DNA methylation results from the activity of
a family of DNA methyl transferases (DNMTs) that
catalyze the addition of a methyl group to cytosine resi-
dues at CpG (5). To date, ﬁve members of the DNMT
family have been described in mammalian cells based
on sequence homology within their C-terminal catalytic
domain but only three of them have been shown to possess
methyltransferase activity. DNMT1 has a preference
toward hemimethylated DNA and is responsible for
maintaining the methylation patterns following DNA
replication (6). The DNMT3 subfamily encodes two
functional cytosine methyltransferases, DNMT3a and
DNMT3b, which are thought to function as de novo
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unmethylated and hemimethylated DNA. DNMT2 and
a third homolog of the DNMT3b subfamily, DNMT3L,
have failed to show cytosine methyltransferase activity (7).
Although Dnmt3a-deﬁcient mice develop to term and
appear to be normal at birth, knockout mice deﬁcient in
either Dnmt1 or Dnmt3b are embryonic lethal (8).
Diﬀerent studies have shown that DNMTs function in
cooperation with each other to facilitate DNA methyla-
tion in both human and mouse systems (9,10). For
instance, the genetic disruption of the human DNMT3b
gene in a colorectal cell line reduced global DNA methy-
lation by less than 3%; however, the genetic disruption of
both DNMT1 and DNMT3b nearly eliminated methyl-
transferase activity and reduced genomic DNA methyla-
tion by greater than 95% (10).
All DNMT proteins contain highly conserved COOH-
terminal catalytic domains while their NH2-terminal
regions are distinct. The NH2-terminal regulatory
domain of each DNMT is thought to direct nuclear local-
ization and to mediate interactions with other proteins.
Among those DNMTs with proven DNA methyltransfer-
ase activity (DNMT1, -3a and -3b), DNMT3b is the
only DNMT that is expressed as alternatively spliced
variants that aﬀect the integrity of the catalytic domain
(11–13). DNMT3b1 and DNMT3b3 are the most highly
expressed (14) although only DNMT3b1 and DNMT3b2
have been shown to be catalytically active (15). The role
of DNMT3b in DNA methylation is unclear, but it seems
to depend on the substrate availability (16,17). The
remaining isoforms (DNMT3b4-6) lack an essential con-
served motif in the catalytic domain required for enzy-
matic activity (14,18). On the other hand, mutations in
human DNMT3b gene (aﬀecting mainly the catalytic
activity) are responsible for the rare autosomal disorder
known as ICF syndrome, characterized by variable immu-
nodeﬁciency, centromeric instability and facial anomalies
(19). ICF patients exhibit naturally occurring DNA
hypomethylation that aﬀects pericentromeric, and sub-
telomeric tandem repeats (19). The speciﬁc roles of indi-
vidual DNMT3b splice variants are not fully understood,
although DNMT3b isoforms are overexpressed in a
variety of human cancers (13). Accordingly, the aberrant
methylation of CpG islands in human cancers could
be due, in part, to the overexpression of DNMT3b.
As the mechanisms underlying the overexpression of
DNMT3b in cancer are still unclear, we set out to investi-
gate this topic.
HuR, a protein that binds to target mRNAs and can
enhance their stability and modulate their translation, is
increasingly recognized as a pivotal regulator of gene
expression. Through its post-transcriptional inﬂuence
on target mRNAs such as those encoding c-fos, c-myc,
cyclooxygenase-2, tumor necrosis factor-a, GM-CSF,
b-catenin, eotaxin, p27, cyclin A, cyclin B1, cyclin D1,
p21, p27, p53 and SIRT1, HuR has been proposed to
play major roles in cell proliferation, tumorigenesis,
the immune response, senescence and the stress response
(20–23). A member of the embryonic abnormal vision
family (ELAV), HuR possesses three RNA-recognition
motifs through which it binds with high aﬃnity and
speciﬁcity to target mRNAs bearing AU- and U-rich
sequences and modiﬁes their expression by altering their
stability, translation, or both (24–26). A signature motif
present in HuR target mRNAs was identiﬁed, with a spe-
ciﬁc U-rich primary sequence and a stem-loop secondary
structure (27). This HuR motif was successfully used
in the prediction of novel HuR target mRNAs such as
VDR, HDAC2 and SIRT1 (20,27). The precise mecha-
nisms whereby HuR mediates the stabilization and/or
translation of target mRNAs are still poorly understood.
However, HuR presence in the cytoplasm appears to
be intimately linked to its mRNA-stabilizing function.
HuR is predominantly (90%) nuclear in most unstimu-
lated cells, but upon cell stimulation, it can translocate
to the cytoplasm where it binds target mRNAs and pre-
vents their decay (26,28,29). Recent studies examining
HuR expression in human cancers revealed that the
abundance and cytoplasmic localization of HuR protein
was signiﬁcantly greater in malignant tissues than in
normal tissues (22,30). Export pathways and signaling
cascades that regulate its cytoplasmic abundance have
been described (28,31,32). A mechanism through which
HuR-binding properties can be modulated has been
recently proposed and occurs through HuR phosphoryla-
tion by Chk2. HuR phosphorylation at S100 was pro-
posed to reduce, while T118 (and to a lesser extent S88)
phosphorylation was proposed to promote HuR binding
to target mRNAs (20).
Although the inﬂuence of stress model agents (e.g. H2O2
and UVC) on HuR function has been studied extensively,
here we sought to test the eﬀect of a chemotherapeutic
drug with clinical relevance. Cisplatin is one of the
most eﬀective anti-cancer drugs, but the mechanisms
underlying its therapeutic action in cancer tissues and its
side eﬀects in normal tissues are largely unclear. An en
masse search for HuR target mRNAs (27) identiﬁed the
DNMT3b mRNA as a putative HuR target and compu-
tationally detected one hit of the HuR consensus motif
in the DNMT3b 30UTR. Given our long-standing interest
in understanding the regulation of DNMTs and DNA
methylation (4,33), and the discovery that the DNMT3b
mRNA is a predicted target of HuR (27), we set out to
investigate if HuR directly regulates the expression of
this methyltransferase. HuR was found to associate with
the DNMT3b mRNA and to enhance its stability, elevat-
ing DNMT3b mRNA steady-state levels. Unexpectedly,
cisplatin treatment lowered DNMT3b mRNA and pro-
tein expression levels in RKO cells and reduced the sta-
bility of the DNMT3b mRNA in a HuR-dependent
manner. This eﬀect was caused by the dissociation
of HuR from the DNMT3b mRNA following cisplatin
treatment, in distinct contrast to the enhanced association
of HuR with numerous target mRNAs in response
to other stress agents. The dissociation of HuR from
the RNP complex was not due to changes in the cytoplas-
mic abundance of HuR, but instead appeared to be
linked to HuR phosphorylation. In turn, modulation of
DNMT3b expression by HuR inﬂuenced global DNA
methylation as well as the methylation of speciﬁc
DNMT3b target DNA.
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Cellculture, treatments andsiRNA transfections
Human colorectal carcinoma RKO cells were cultured in
minimum essential medium (Invitrogen), supplemented
with 10% fetal bovine serum and antibiotics. Cells were
subjected to Cisplatin (Sigma) treatment at the concentra-
tions and times speciﬁed in each experiment. Small inter-
fering RNA (siRNA) targeting HuR was AAGAGGCAA
TTACCAGTTTCA, DNMT3b siRNA was CAGCTCTT
ACCTTACCATCGA and the control siRNA was AATT
CTCCGAACGTGTCACGT; siRNAs (50nM, Qiagen)
were transfected with Oligofectamine (Invitrogen), and
cells were harvested 2–3 days after transfection, as indi-
cated. Lipofectamine 2000 (Invitrogen) was used when
plasmids were cotransfected.
Immunoprecipitation ofRNP complexes
Immunoprecipitation (IP) of HuR–mRNA complexes
from RKO cell lysates was used to assess the association
of endogenous HuR with endogenous target mRNAs. The
IP assay was performed essentially as described (27,34),
except that 100 million cells were used as starting material
and the lysate supernatants were precleared for 30min
at 48C using 15mg of immunoglobulin G (IgG) (Santa
Cruz Biotechnology) and 50ml of protein A-Sepharose
beads (Sigma) that had been previously swollen in NT2
buﬀer [50mM Tris (pH 7.4), 150mM NaCl, 1mM MgCl2
and 0.05% Nonidet P-40 (NP-40)] supplemented with 5%
bovine serum albumin. Beads (100ml) were incubated
(18h, 48C) with 30mg of antibody (either mouse IgG
[Santa Cruz Biotechnology] or mouse anti-HuR [Santa
Cruz Biotechnology]) and then for 1h at 48C with 3mg
of cell lysate. After extensive washes and digestion of pro-
teins in the IP material (34), the RNA was extracted
and used to perform reverse transcription (RT) followed
by semiquantitative PCR or quantitative PCR (qPCR)
to detect the presence of speciﬁc target mRNAs using
gene-speciﬁc primer pairs. GAPDH mRNA was used
to normalize the data. All oligonucleotide pairs (50 and
30 primers, respectively) used are listed in Supplementary
Data.
As with all RNP IP data, we routinely normalized the
results and assessed diﬀerences in mRNA input by
measuring two parameters. First, we measured in parallel
the binding of, e.g. DNMT3b mRNA to IgG and to anti-
HuR antibodies. Therefore, if the lysate contained diﬀer-
ent levels of DNMT3b mRNA, these would have been
reﬂected as background association of the mRNA to
IgG and beads in the IgG IP samples; the levels of
DNMT3b associated with HuR in the HuR IP samples
would then reﬂect the ‘Fold enrichment’ of DNMT3b
mRNA in HuR IP relative to IgG IP. Second, we routi-
nely measured (in both HuR IP and IgG IP) the levels
of GAPDH mRNA. The GAPDH mRNA is not a
target of HuR, but it is an abundant transcript in all
RNA preparations and can thus be easily measured as
a contaminant in the IP beads, plastic of the microfuge
tube, etc. Thus, if there were any minor diﬀerences
in RNA input, these diﬀerences would be measured by
quantifying the non-speciﬁc presence of GAPDH
mRNA in IP materials. Statistical analysis was performed
using the Wilcoxon test.
Synthesis ofbiotinylated transcripts and
biotin pull-down analysis
For in vitro synthesis of biotinylated transcripts, reverse-
transcribed total RNA was used as the template for
PCR ampliﬁcation using 50oligonucleotides that con-
tained the T7 RNA polymerase promoter sequence. See
Supplementary Data for information on the oligonucleo-
tide pairs used. The PCR-ampliﬁed products were
resolved on agarose gels and the transcripts were puriﬁed
and used as templates for the synthesis of the correspond-
ing biotinylated RNAs using T7 RNA polymerase and
biotin-CTP (26). Biotin pull-down assays (26) were carried
out by incubating 40mg of cytoplasmic lysate with
0.2mg of biotinylated transcripts for 30min at room
temperature. Complexes were isolated using streptavidin-
conjugated Dynabeads (Dynal), and bound proteins in the
pull-down material were analyzed by western blotting
using antibodies recognizing HuR (below).
Western blot analysis
Whole-cell lysates were prepared using RIPA buﬀer, as
described (35). For the preparation of cytosolic fractions,
cells were scraped in 500ml of RSB lysis buﬀer (10mM
Tris–HCl pH 7.5, 10mM NaCl, 3mM MgCl2, and inhibi-
tors). After the addition of 1% NP-40, the lysate was
incubated on ice for 20min and centrifuged (2000r.p.m.,
5min, 48C), and the supernatant was designated as the
soluble cytosolic fraction. The pellet was washed once
with RSB/1% NP-40 and twice with RSB before adding
NB buﬀer (10mM Tris–HCl pH 7.4, 400mM NaCl, 1mM
EDTA and inhibitors), mixed thoroughly for 15min at
48C and centrifuged (11000r.p.m., 5min, 48C), to obtain
the nuclear fraction. Protein lysates were resolved
by SDS–PAGE and transferred onto nitrocellulose
membranes. Antibodies used to detect HuR, Chk2, phos-
pho-Chk2, b-tubulin and Nucleolin (C23) were from
Santa Cruz Biotechnology. A monoclonal antibody-
recognizing a-Tubulin was from Sigma. Following
secondary antibody incubations, signals were visualized
by enhanced chemiluminescence.
mRNA stability
For mRNA half-life assessments, three independent
experiments were performed. Actinomycin D (5mg/ml)
was added and total RNA was prepared at the times
indicated; mRNA half-lives were calculated after quanti-
fying by RT–qPCR, normalizing to 18S RNA levels
(using a 1:20 dilution of the stock sample), plotting on
logarithmic scales using GraphPad Prism, and calculating
the time period required for a given transcript to undergo
a reduction to one-half of its initial abundance (at time
zero, before adding actinomycin D) using non-linear
regression analysis.
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For construction of pMIR-DNMT3b and pMIR-
GAPDH, PCR products were prepared with primers
spanning the corresponding 30UTRs of each gene
(Supplementary Data) and cloned into the SpeI/HindIII
site of plasmid pMIR-report (Ambion). Transient trans-
fection of RKO cultures with pMIR, pMIR-DNMT3b
or pMIR-GAPDH was carried out using Lipofectamine
2000 (Invitrogen). Cotransfection of pGL4 plasmid
containing Renilla (Promega) served as an internal
control. Fireﬂy and Renilla Luciferase activities were
measured with the Dual Luciferase Reporter Assay
System (Promega), following the manufacturer’s instruc-
tions. All Fireﬂy luciferase measurements were normal-
ized to Renilla luciferase measurements from the same
sample. Statistical analysis was performed using the
Wilcoxon test.
Quantification of global 5-methylcytosine content
Brieﬂy, genomic DNA samples were boiled, treated with
nuclease P1 (Sigma) for 16h at 378C, and with alkaline
phosphatase (Sigma) for an additional 2h at 378C. After
hydrolysis, total cytosine and 5 mC content were mea-
sured by HPLC-MS in all samples. The LC-ESI/MS
system consisted of an Agilent Series 1100 HPLC system
coupled to an Agilent LC/MSD VL mass spectrometer
equipped with an electrospray ionization source (Agilent
Technology, Palo Alto, CA). Fifty microliters of the
hydrolyzed-DNA solution were injected onto an Atlantis
dC18 column (2.1 150mm; 5mm particle size) pro-
tected by an Agilent guard column (2.1 20mm; 5mm
particle size) at a constant ﬂow of 0.220ml min
 1. Two
buﬀers, 0.1% formic acid in water (Solvent A) and 0.1%
formic acid in 50% water: 50% methanol (Solvent B),
were used, with a initial gradient of 5% solvent B, then
an increase of solvent B to 50% within 9min and an
isocratic gradient (50% of solvent B) during 25min.
Electrospray source conditions were as described in
Friso et al. (36), with minor modiﬁcations. A drying
gas ﬂow of 10.0l min
 1 was employed, with auxiliary
35psi gas to assist with nebulization and a drying temper-
ature of 3508C. The mass spectrophotometer was
operated at a capillary voltage of 4000V, and spectra
were collected in positive ion mode. Identiﬁcation of
20-deoxycytidine (dC) and 5-methyl-20-deoxycytidine
(5 mdC) was obtained by UV detection at A254 and
A280. Quantiﬁcation of global DNA methylation were
calculated from integration peak areas of 5 mdC relative
to global cytidine (5 mdC+dC). Statistical analysis was
performed using an unpaired two-tailed Student t-test
with Welch correction.
Analysis ofsequence-specific DNA methylation
The methylation status of speciﬁc genomic DNA sequences
was established by bisulﬁte genomic sequencing (37).
Automatic sequencing of 10 colonies for each sequence
was performed to obtain data on the methylation sta-
tus of every single CpG dinucleotide. Statistical analysis
was performed using the McNemar test. Primer sequences
are available as Supplementary Data.
RNA extraction, RT and semi-quantitative and qPCR
Total RNA was isolated using phenol/chloroform/isoamyl
alcohol, according to manufacturer’s protocol (Ambion).
Five-microgram aliquots were used to perform RT using
random hexamers followed by semiquantitative PCR
(semiq-PRC) or qPCR to detect the presence of speciﬁc
amplicons. For semiq-PCR, PCR conditions were 958C
for 7min followed by a variable number of cycles (n)o f
958C for 30s, annealing temperature for 30s and 728C for
30s; a ﬁnal extension was performed at 728C for 10min.
The parameter ‘n’ varied depending on the Ct value of the
gene (calculated by qPCR); three diﬀerent n cycles were
performed per gene around its Ct value. PCR products
were visualized after electrophoresis in 1% agarose gels
stained with ethidium bromide. Analysis of real-time
qPCR ampliﬁcation of the cDNA was performed using
SYBR Green PCR Master Mix (Applied Biosystems)
in a 7900HT fast Real-time PCR System (Applied
Biosystems). PCR conditions were 508C for 2min, 958C
for 10min followed by 40 cycles of 958C for 15s and 608C
for 1min. Assays were normalized to GAPDH mRNA
levels.
RESULTS
HuR associateswith DNMT3b mRNA
Of the six alternatively spliced transcript variants that
have been identiﬁed for the human DNMT3b gene, only
the full-length sequences of variants 1, 2, 3 and 6 have
been determined (Figure 1A). The 30UTRs of these four
DNMT3b transcripts variants are identical, span 1465nt,
and are found to have one computationally predicted hit
of an HuR motif in their 30UTR (27). No HuR hits
were found in the mouse DNMT3b gene (27), suggesting
that this feature may not be shared among mammalian
systems. The identiﬁcation of the HuR motif in the
human DNMT3b predicted that all of the transcript
variants could be direct targets of HuR (Figure 1B). To
test this possibility, we ﬁrst assessed whether DNMT3b
mRNA associated with HuR by performing immuno-
precipitation (IP) assays using anti-HuR antibodies
under conditions that preserved the composition of
[HuR-mRNAs] RNP complexes. IP was carried out in
RKO cells transfected with either control (C) or HuR
siRNA, the latter treatment eliciting a signiﬁcant reduc-
tion in HuR levels (5–10% of the HuR levels seen in the
control transfection group, Figure 1C). The endogenous
association of DNMT3b mRNA with HuR was
monitored by isolating RNA from the IP material and
subjecting it to RT followed by PCR and quantitative
(q) real-time PCR analysis. The DNMT3b primers used
for PCR analysis were designed to amplify four diﬀerent
bands; among these, the top band corresponds to variants
1, 2 and 6, and the bottom one to variant 3. Two addi-
tional weaker bands can be detected between the top
and bottom bands which correspond to variants 4 and
5. For qPCR analysis, speciﬁc primers against variant 3
Nucleic Acids Research,2009, Vol.37, No. 8 2661were used. As shown in Figure 1D (graph and inset), the
DNMT3b PCR products were dramatically enriched in
HuR IP in C siRNA samples compared with control
IgG IP samples. For instance, variant 3 was enriched a
striking  50-fold in the HuR IP as compared with the IgG
IP. The absence of enrichment of DNMT3b mRNA in
HuR siRNA cells in HuR IP compared with IgG IP sup-
ports the speciﬁcity of this association. The ampliﬁcation
of a GAPDH PCR product, found in all samples as a
low-level contaminating housekeeping transcript, further
indicated the speciﬁcity of the interaction between HuR
and target mRNAs and served to monitor the evenness
of sample input.
[HuR-DNMT3b mRNA] associations were further
tested by using biotinylated transcripts spanning the
mRNA regions shown (Figure 2, schematic; the star
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Figure 1. HuR associates with the endogenous DNMT3b mRNA. (A) The four alternatively spliced transcript variants for the DNMT3b gene. (B)
DNMT3b 30UTR showing one predicted HuR motif hit. (C) Two days after siRNA transfection, RKO cells were harvested for western blot analysis
to monitor the expression of HuR and loading control a-Tubulin. (D) RKO cells were transfected with either control (C) or HuR siRNA and the
lysates were used in IP reactions employing anti-HuR antibodies or control IgG1; RNA was subsequently isolated and used in RT reactions (inset).
Representative PCR products of all DNMT3b variants visualized in ethidium bromide-stained agarose gels; the levels of GAPDH (a housekeeping
mRNA which is not a target of HuR) served to verify equal sample input. (Graph) Fold diﬀerences in DNMT3b variant 3 mRNA abundance in
HuR IP compared with IgG IP, as measured by RT–qPCR analysis. The means and standard error of the means (SEM) from three independent
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2662 Nucleic Acids Research, 2009, Vol. 37,No. 8represents the position of the HuR motif within the
30UTR). Following incubation with RKO cytoplasmic
lysates, the interaction between HuR and the diﬀerent
biotinylated transcripts was assessed by biotin pull-down
followed by western blot analysis. As shown, HuR only
formed complexes with the 30UTR-DNMT3b (Figure 2).
Interestingly, not only did the biotinylated transcript
30UTR-B (predicted to contain the HuR motif hit) bind
to HuR, but the 30UTR-A transcript (common to all
DNMT3b variants) also showed association with HuR,
indicating that HuR could interact with multiple regions
of the DNMT3b 30UTR. Supporting this notion is the
ﬁnding that HuR bound to fragments B1 and B2, which
also lack the HuR motif. In the RNP analysis, biotiny-
lated GAPDH 30UTR (not a target of HuR) served as
a negative control transcript while biotinylated p53
30UTR (a reported HuR target), was used as a positive
control. Interestingly, 45% of the cytoplasmic HuR was
pulled down with the entire 30UTR (FL fragment)
(Figure 2, graph). We cannot establish whether this asso-
ciation implicated ‘free’ cytoplasmic HuR or HuR that
was previously bound to endogenous mRNAs since
microccocal nuclease was not added to the samples.
Together, these ﬁndings indicate that HuR speciﬁcally
associates with all of the DNMT3b variants, both endo-
genous and in vitro biotinylated, and that this interaction
occurs in at least three diﬀerent positions of the DNMT3b
30UTR. From this point forward, unless indicated, the
studies have been performed with the DNMT3b variant
3 because it is one of the most abundant splice variants.
HuR stabilizes theDNMT3b mRNA
To assess the functional consequences of [HuR-DNMT3b
mRNA] interactions, we ﬁrst measured DNMT3b mRNA
levels after silencing HuR. In cells with lowered HuR
expression, the steady-state levels of DNMT3b mRNA
were reduced by 25% when compared with C siRNA
cells; a speciﬁc pair of primers were used for RT–qPCR
to detect all spliced variants in one single PCR product
(Supplementary Data), while a primer pair that speciﬁ-
cally detected variant 3 revealed a 12% reduction for
this variant (Figure 3A). Since the 30UTR of the four
DNMT3b variants (1, 2, 3 and 6) is identical, these diﬀer-
ences might be due to speciﬁc sequences in the 50UTR
and CR (Figure 1A). The DNMT3b protein levels could
not be studied by western blot or immunoﬂuorescence
analyses using any of the commercially available
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abundance (discontinuous horizontal line). Data represent the mean 
SEM from three independent experiments.
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Figure 2. HuR associates in vitro with the DNMT3b mRNA.
Schematic representation of the DNMT3b-biotinylated transcripts
[CR, CR fragments (A and B), entire 30UTR (FL), partial 30UTR
(A, B, B1 and B2)] used in biotin pulldown assays. The presence
of HuR in the pulldown material was assayed by western blotting;
biotinylated GAPDH 30UTR was included as a negative control. The
star represents the position of the HuR motif.
Nucleic Acids Research,2009, Vol.37, No. 8 2663antibodies (data not shown). Contributing to the diﬃ-
culty in detecting DNMT3b is the fact that DNMT3b
protein levels in cancer cell lines is low as compared to
the high levels seen in diﬀerentiated embryoid bodies (11).
To ascertain if the reduction in the DNMT3b mRNA
levels was due to changes in mRNA stability, the
DNMT3b mRNA stability (t1/2) was analyzed following
treatment with actinomycin D to inhibit de novo
transcription. The levels of DNMT3b mRNA and the
housekeeping control GAPDH mRNA were monitored
by RT followed by semiquantitative PCR (using primers
that amplify all the DNMT3b variants in diﬀerent
PCR products) and qPCR (using primers that amplify
DNMT3b variant 3) (Figure 3B, gel images and graph,
respectively). As shown, DNMT3b mRNA was found
to be signiﬁcantly more stable in the control siRNA (C)
transfection group, with an estimated t1/2=4.75h
for variant 3, while DNMT3b mRNA stability was
markedly reduced in the HuR siRNA group, with
t1/2=2.22h for variant 3 (Figure 3B). GAPDH mRNA,
a very stable mRNA (t1/2>8h) did not show diﬀerences
between transfection groups, in agreement with the
fact that GAPDH mRNA is not a target of HuR target.
In summary, HuR speciﬁcally enhanced DNMT3b
mRNA stability.
Cisplatin treatment dissociates [HuR-DNMT3b mRNA]
complexes, reduces DNMT3b mRNA stability and
lowers DNMT3b mRNA abundance
HuR responds rapidly to cellular stress by increasing or
decreasing its association to mRNA target genes impli-
cated in cell survival (20,26). Therefore, we extended our
studies to examine the functional inﬂuence of HuR upon
DNMT3b mRNA in response to stress. Exposure of
RKO cells to cisplatin (50mM, 8h) caused a signiﬁcant
reduction of DNMT3b mRNA levels as compared with
untreated cells (Figure 4A). Unexpectedly, the stability
of the DNMT3b mRNA was reduced after cisplatin treat-
ment in C siRNA cells (Figure 4B) and HuR siRNA
cells (Supplementary Figure 1) as compared to untreated
C siRNA cells, suggesting that the lower DNMT3b
mRNA abundance (Figure 4A) was due, at least in part,
to a cisplatin-triggered decrease in its half-life. The
reduction in DNMT3b mRNA levels was further
accentuated after treatment with cisplatin, even in cells
with silenced HuR, raising the possibility that mecha-
nisms other than dissociation from HuR could also con-
tribute to the loss of DNMT3b mRNA after cisplatin
treatment.
To determine if the reduced DNMT3b mRNA stability
after cisplatin treatment was linked to changes in its asso-
ciation with HuR, the levels of these complexes was
tested by RNP IP analysis. The amount of DNMT3b
mRNA that is constitutively bound to HuR was substan-
tially reduced by the cisplatin treatment, as monitored by
RT–qPCR (Figure 5). The reduction in [HuR-DNMT3b
mRNA] complexes was time-dependent, decreasing to
almost background levels by 2h after cisplatin treatment,
whereas total DNMT3b mRNA levels decreased more
slowly, with only a 25–30% decline in variant 3 levels
by 8h after cisplatin treatment, suggesting that the disso-
ciation of this RNP preceded the decay of DNMT3b
mRNA (Figures 4A and 5). The association of HuR
to other known HuR target transcripts (PTMA, SIRT1,
Cyclin D1 and MKP-1 mRNAs) follow distinct
patterns and kinetics of binding, indicating that HuR
speciﬁcally dissociated from DNMT3b mRNA after
cisplatin treatment (Figure 5). These observations are
consistent with a model whereby cisplatin treatment
dissociates DNMT3b mRNA from HuR, in turn trigger-
ing DNMT3b mRNA destabilization and reducing
DNMT3b mRNA levels.
The inﬂuence of HuR upon the expression of DNMT3b
was further studied through the construction and analysis
of luciferase reporter vectors linked to either the full-
length DNMT3b 30UTR or the full-length GAPDH
30UTR (Figure 6A, schematic). Following transient trans-
fection with the diﬀerent plasmid constructs, the measure-
ment of luciferase activity showed a marked decrease in
the HuR siRNA and cisplatin-treated groups (Figure 6A).
Fragments B1, B2 and, to a lesser extent fragment A
(Figure 2) recapitulate the eﬀects seen with the full-
length DNMT3b 30UTR (Supplementary Figure 2).
Importantly, this reduction was consistent with destabili-
zation of the mRNA, as suggested by the qPCR analysis
of the 30UTR-luc mRNA levels (Figure 6B).
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Figure 4. Cisplatin treatment decreases DNMT3b mRNA stability and
steady-state levels. (A) Two days after siRNA transfection, cells were
treated with 50mM cisplatin for 8h, RNA was isolated and RT–qPCR
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2664 Nucleic Acids Research, 2009, Vol. 37,No. 8Cisplatin treatment doesnot changethe subcellular
localization of HuR
Changes in HuR association to target mRNAs have been
largely linked to HuR presence in the cytoplasm. To test
if the dissociation of HuR from DNMT3b mRNA after
cisplatin treatment was due to changes in HuR cytoplas-
mic abundance, nuclear and cytoplasmic fractions were
collected at diﬀerent incubation times with cisplatin.
Unexpectedly, western blot analysis showed no signiﬁcant
changes in HuR cytoplasmic levels in response to cisplatin
(Figure 7). Immunoﬂuorescence staining conﬁrmed the
absence of changes (data not shown).
As reported in other cells systems (38), cisplatin treat-
ment triggered the phosphorylation and therefore the
activation of the cell cycle checkpoint kinase Chk2 in
RKO cells (Supplementary Figure 3A). This ﬁnding was
particularly important because Chk2 phosphorylates and
thereby regulates HuR binding to target mRNAs (20),
suggesting that this modiﬁcation was a potential mecha-
nism responsible for the dissociation of HuR from
DNMT3b mRNA after cisplatin treatment. Preliminary
data indicate that this is the case as slight shifts in HuR
signals were observed by 2D SDS–PAGE after cisplatin
treatment (Supplementary Figure 3B).
HuR binding toDNMT3b mRNA influences globalDNA
methylation as well as the methylation ofspecific
DNMT3b target DNA
We determined whether global DNA methylation was
aﬀected by the lowering of DNMT3b levels by HuR.
Total cytosine and 5 mC content were measured by
high-performance liquid chromatography coupled with
mass spectroscopy (HPLC-MS). The percentage of 5
mC relative to the total cytosine content was reduced
in both by HuR silencing and by cisplatin treatment
(Figure 8A). To study if the decrease in global DNA
methylation was due, at least in part, to a direct eﬀect of
the DNMT3b activity, we performed bisulﬁte sequenc-
ing on two speciﬁc DNA regions that undergo hypo-
methylation in the ICF syndrome, which is caused by
DNMT3b mutations that often aﬀect its methyl-
transferase activity. Bisulﬁte sequencing analysis showed
a signiﬁcant decrease in the methylation of the pericentro-
meric region Sat2 and the subtelomeric D4Z4 tandem
repeats in dependence on HuR levels and after cisplatin
treatment (Figure 8B).
To further strengthen these ﬁndings, we extended the
analysis of global and regional DNA methylation to
cells in which DNMT3b expression was silenced by trans-
fection with a speciﬁc siRNA. DNMT3b knockdown
reduced DNMT3b mRNA levels down to  30% of the
levels present in the control transfected cells (Figure 9A).
As expected, this intervention caused a reduction in 5 mC
content comparable to what was seen after silencing
HuR (Figure 9B). Regarding the regional methylation,
cells with silenced DNMT3b also showed results compa-
rable to what was seen after HuR silencing (Figure 9C).
Taken together, these observations indicate that HuR
association with the DNMT3b mRNA inﬂuences its
expression and activity, which in turn aﬀects global geno-
mic methylation and DNMT3b-speciﬁc methylation.
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HuR dissociation from DNMT3b
The correct regulation of the DNMT3b gene is critical
for the maintenance of normal DNA-methylation pat-
terns. Point mutations in human DNMT3b (usually in
the catalytic domain) are responsible for the rare auto-
somal recessive disorder known as ICF (immunodeﬁ-
ciency, centromere instability and facial anomalies)
syndrome. ICF patients’ exhibit a loss of methylation
at selected centromeric regions and have profound chro-
mosomal structural changes (39). DNMT3b levels are
deregulated in cancer and are found to be elevated in a
variety of cancer tissues as compared to their normal
counterparts (12,14,40–42). Although elevations in
DNMT3b levels were long suspected to cause promoter
hypermethylation, a common hallmark of cancer, experi-
mental evidence to support this notion was only recently
obtained (43). Here, we show that HuR associates with the
DNMT3b mRNA and regulates its expression by enhanc-
ing DNMT3b mRNA stability. Surprisingly, cisplatin
treatment dissociated [HuR-DNMT3b mRNA] RNP
complexes, triggering a reduction in DNMT3b mRNA
half-life, which in turn decreased DNMT3b expression
and activity.
It was interesting to ﬁnd that the reduced association
of HuR and DNMT3b did not arise from changes in
HuR cytoplasmic abundance, the main mechanism pro-
posed to regulate HuR function to-date (44). In fact, the
extensively documented HuR translocation to the cyto-
plasm in response to cellular stress has been linked
to the increase association of HuR to target mRNAs
(22,26,45,46). This was the case for several transcripts
(e.g. p21, p53, PTMA and cyclin D1 mRNAs), whose
association to HuR increased after irradiation of the
cells with UVC (short-wavelength ultraviolet) light
(25,26,47) or after cisplatin treatment, as shown in this
study (Figure 5). Here, despite extensive analysis of
the subcellular localization of HuR after cisplatin treat-
ment, we failed to detect any signiﬁcant changes in cyto-
plasmic HuR levels by either western blot analysis
(Figure 7) or immunoﬂuorescence (data not shown).
Interestingly, the association of HuR with target
mRNAs was recently shown to be modulated by a mech-
anism involving the phosphorylation of HuR via the
kinase Chk2/Cds1 (20), This phosphorylation aﬀects
HuR binding in distinct ways depending on which resi-
due is phosphorylated and on the target mRNA. This
new mechanism prompted us to analyze the activation
of Chk2 after cisplatin treatment. As shown previously
(38), cisplatin activated Chk2 (Supplementary
Figure 3A), associated with a modest shift in HuR signals
by 2D western blot analysis (Supplementary Figure 3B)
suggesting that HuR likely becomes phosphorylated
in response to cisplatin. This, in turn could lead to the
disassembly of HuR from the RNP complex, as shown
after activation of Chk2 following exposure to H2O2
(20). Therefore, Chk2 is one potential candidate to explain
the loss of HuR binding to DNMT3b mRNA, but this pos-
sibility awaits further experimental testing. An additional
explanation for the dissociation of [HuR-DNMT3n
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Figure 6. HuR levels and cisplatin treatment aﬀect the activity of a
reporter construct bearing the DNMT3b 30UTR. Two days after
siRNA transfections, the expression vector pMIR-report (ﬁreﬂy
luciferase reporter system) containing either DNMT3b 30UTR
(pMIR-30UTR) or GAPDH 30UTR (pMIR-GAPDH) were transiently
cotransfected into RKO cells along with pGL4-Renilla (used to nor-
malize for transfection eﬃciency); 24h later, cells were treated with
cisplatin (50mM, 8h), and protein and RNA were collected. (A)
Protein extracts were used for the detection of ﬁreﬂy and renilla
luciferase activities. Graph shows the relative fold increase in ﬁreﬂy
luciferase activity seen in the pMIR-DNMT3b transfection group
relative to pMIR-GAPDH after normalization to renilla activity.
Values represent the means   SEM from three independent experi-
ments ( P 0.05). (B) Reverse-transcribed RNA was used for qPCR
detection of the reporter DNMT3b 30UTR-luciferase mRNA relative to
the GAPDH 30UTR-luciferase mRNA. Transfection eﬃciency was
normalized to the amount of pMIR vector present in each sample,
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Figure 7. Cisplatin does not change cytoplasmic HuR levels. Nuclear
and cytoplasmic HuR levels were assessed by western blot analysis of
RKO cells that were either left untreated or were treated with 50mM
cisplatin for the times shown. a-Tubulin and Nucleolin signals served
to show the quality of the preparation of cytoplasmic and nuclear
fractions, respectively.
2666 Nucleic Acids Research, 2009, Vol. 37,No. 8mRNA] complex could be the induction of conforma-
tional changes in the DNMT3b mRNA due to the for-
mation of cisplatin–RNA adducts. The N7 atoms of
guanine and adenine are the main binding sites for cispla-
tin; the resulting adducts could trigger the formation
of intra- or interstrand crosslinks, causing local distortions
in the nucleic acid structure (48). As the secondary struc-
ture of a previously deﬁned HuR signature motif is a
stem-loop (27), cisplatin could alter its conformation,
thereby inducing the dissociation of HuR from the
mRNA. Whether HuR regulates the DNMT3b mRNA
stability in response to other stimuli also remains to be
tested, but treatment with trichostatin A (TSA, a histone
deacetylase inhibitor) lowered DNMT3b mRNA stability
(49). Although the authors of this report did not identify
the factor(s) implicated in this regulation, it will be inter-
esting to study if challenge with drugs that alter chromatin
structure also dissociates HuR from target DNMT3b
mRNA.
Coordinateregulation of DNMT3b
The RNA operon theory posits that multiple mRNAs are
co-ordinately regulated by RNA-binding proteins and
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Nucleic Acids Research,2009, Vol.37, No. 8 2667small non-coding RNAs (50). The regulation of DNMT3b
mRNA splice variants by HuR supports this concept.
HuR binds to the DNMT3b mRNA in at least three
diﬀerent regions of the 30UTR (Figures 1D and 2,
biotinylated fragments A, B1 and B2). The presence of
multiple binding sites within the 30UTR is becoming a
common feature among HuR targets mRNA described
in the recent years. For instance, Kawai and colleagues
found that HuR binds to three diﬀerent regions of
the cytocrome c 30UTR (51) while the MKP-1 30UTR
showed HuR binding to two non-overlapping segments
(24). Why are there multiple HuR-binding sites within
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2668 Nucleic Acids Research, 2009, Vol. 37,No. 8a single 30UTR? Maybe it is to ensure that HuR binds
a given mRNA, even under strong pressure from other
competing RNA-binding proteins and/or miRNAs with
aﬃnities for the same sequences. Supporting this idea is
the fact that some of these HuR-binding regions are
also bound by other RNA-binding proteins whereas
others are exclusively bound by HuR (24,51,52). In the
MKP-1 mRNA, a distal biotinylated fragment (C) was
bound by HuR, NF90 and TIAR while a middle fragment
(B) was only bound by HuR and TIAR (24). Interestingly,
we found that AUF1 and to a lesser extent TIA-1 and
TIAR, also associated with the DNMT3b mRNA
(Supplementary Figure 4). It will be interesting to analyze
if they bind to the same regions as HuR. The combination
of multiple mRNAs and RNA-binding protein in an
RNA operon can help to dynamically determine the abun-
dance and translational status of a given mRNA following
biological perturbations. Highlighting this paradigm is
the fact that, similar to HuR, AUF1 [which targets for
mRNA degradation and has been recently shown to
control translation as well (53)] dissociates almost com-
pletely from DNMT3b mRNA after cisplatin treatment;
by contrast, TIA-1 and TIAR (both translational inhibi-
tors) associate slightly more with the DNMT3b mRNA
(Supplementary Figure 4). The changes in binding
patterns might be essential in order to meet the require-
ments of the cell. For instance, the fact that DNMT3b
protein is absent in certain stages of germ cell development
despite the presence of some of its transcripts (54) suggests
the involvement of these translational inhibitors or possi-
bly miRNAs. An additional layer of complexity in this
process is potentially provided by miR-29, which binds
the DNMT3b3 30UTR [(55) and data not shown)] and
miR-148, which binds the coding regions of these tran-
scripts with the exception of DNMT3b3 mRNA (56).
A scenario wherein multiple trans-acting factors regu-
late the DNMT3b mRNA could help us to explain the
discrepancies that we found in the reduction of
DNMT3b mRNA half life (>2-fold) and the changes
in steady-state levels (decreased by only 15–25%) when
HuR protein levels are reduced. HuR silencing, which
clearly reduced DNMT3b mRNA stability (Figure 3C),
might permit access to other trans-acting factors
(RNA-binding proteins and/or miRNAs) which can fur-
ther inﬂuence the post-transcriptional metabolism of
DNMT3b mRNA levels (for example, binding by TIA1
and TIAR might repress DNMT3b translation). There-
fore, all the factors that we also found to associate with
the DNMT3b 30UTR (Supplementary Figure 4) should
be taken into account, as they will likely inﬂuence the
ﬁnal expression levels of DNMT3b. It is also important
to note that the mRNA stability is measured after shutting
oﬀ transcription; thus, we cannot formally exclude
the possibilities that DNMT3b levels might be transcrip-
tionally regulated (for instance, transcription could
increase to balance the loss of DNMT3b mRNA levels).
It also remains possible that the nuclear processing of
DNMT3b mRNA and its cytoplasmic export are altered
by cisplatin treatment.
All the above considerations could also help to explain
the discrepancies we found in the luciferase experiments,
as luciferase activity in reporters bearing the DNMT3b
30UTR were lowered from 0.8 to 0.2 relative units versus
mRNA reduction from 1.6 units to <0.1 units when HuR
was silenced (Figure 6). It is possible that the aforemen-
tioned factors could also be recruited to regulate the endo-
genous DNMT3b mRNA. In summary, these results
indicate that the DNMT3b is tightly regulated through
multiple levels of regulation. HuR is a potent regulator
of DNMT3b mRNA stability but additional trans-acting
factors (RNA-binding proteins and miRNAs) and other
levels of regulation (transcription, other mRNA proces-
sing) likely help to determine the ﬁnal levels of the
DNMT3b mRNA and protein.
Influence of cisplatinon HuR function
The ﬁnding that cisplatin treatment altered HuR-binding
properties has important implications in cancer. Firstly,
HuR levels are upregulated in a wide variety of cancers
(22,30,57–59). Several studies focusing on cancers of the
breast, colon, lung and ovary report a correlation between
HuR expression levels and advancing stages of
malignancy, supporting a role for HuR in these cancer
types (22,57,60,61). HuR is proposed to play an important
role in cancer by binding to mRNAs-encoding proteins
that participate in malignant transformation (e.g. c-fos,
c-myc, COX-2, VEGF and MMP), and modulating
their expression via mRNA stabilization and/or altered
translation (22,23). Secondly, the cancer-associated over-
expression of HuR might contribute to the altered levels
of DNMT3b found in many diﬀerent types of cancer tis-
sues (14,41,42,62). Hypermethylation of the CpG islands
in the promoter regions is a common event in many can-
cers (4). A link between promoter hypermethylation
in cancer and DNMT3b was revealed by recent studies
which suggested that DNNMT3b was required for
tumour development (63) and that the in vivo overexpres-
sion of DNMT3b1 caused a loss of imprinting and
methylation, leading to the transcriptional silencing of
tumour suppressor genes (43). Thirdly, cisplatin is
one of the most eﬀective chemotherapeutic agents for
cancer treatment. Cisplatin–DNA adducts activate var-
ious signal-transduction pathways implicated in DNA–
damage recognition and repair, cell-cycle arrest and
programmed cell death/apoptosis (48). The ﬁnding that
cisplatin reduces the binding of HuR to DNMT3b
mRNA (and likely other targets) indicate that HuR
could be an eﬀector of the changes in gene expression
patterns elicited by cisplatin treatment. It will be interest-
ing to evaluate globally the inﬂuence of cisplatin on HuR
binding to target mRNAs, particularly those which sup-
press apoptosis such as PTMA (47). The results presented
here underscore the importance of HuR as a novel down-
stream target of cisplatin, pointing to new molecular
mechanisms of cisplatin action.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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